Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 3 Mesothelioma, Malignant 3 Carcinoma, Non-Small-Cell Lung 3 Pancreatic Neoplasms 1 Non Hematologic Cancers 1 Neoplasms, Mesothelial 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Lung Neoplasms 1 Low Grade Serous Ovarian Cancer 1 Carcinoma, Ovarian Epithelial 1 Adenoma 1

Interventions

pembrolizumab 133 Gemcitabine 101 Paclitaxel 100 Carboplatin 84 Nivolumab 66 Docetaxel 62 Bevacizumab 62 Cisplatin 57 Pemetrexed 50 Fluorouracil 49 Cyclophosphamide 41 Cetuximab 41 trametinib 38 venetoclax 37 Leucovorin 37 Irinotecan 37 Sorafenib 35 Capecitabine 35 Ipilimumab 33 Dexamethasone 32 atezolizumab 31 Erlotinib Hydrochloride 28 130-nm albumin-bound paclitaxel 28 Drug Therapy 27 Epoetin Alfa 26 Doxorubicin 25 Oxaliplatin 24 Albumin-Bound Paclitaxel 24 Prednisone 23 Rituximab 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × defactinib × Clear all

NCT00787033 2017-01-25

B0761001

Verastem, Inc.

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡